Indeed, peptide therapy is well accepted in clinical use, as for example with the widely used glucagon-like peptide 1 (GLP-1) in type 2 diabetes for lowering blood glucose levels [48]. This evidence concerns the gene GCG and type 2 diabetes mellitus.